Search

Your search keyword '"Sulkowski, Mark S"' showing total 218 results

Search Constraints

Start Over You searched for: Author "Sulkowski, Mark S" Remove constraint Author: "Sulkowski, Mark S" Database Unpaywall Remove constraint Database: Unpaywall
218 results on '"Sulkowski, Mark S"'

Search Results

1. WED-379 Intrahepatic changes in immunologic and virologic markers during siRNA JNJ-73763989 (JNJ-3989) based treatment of chronic hepatitis B (CHB) patients: imaging mass cytometry (IMC) analyses from the INSIGHT study

2. Cardiometabolic health in people with HIV: expert consensus review

3. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

4. Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs

5. Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study

6. Intrahepatic characterization of virological and immunological markers in two distinct populations of chronic hepatitis B: baseline assessment of core liver and fine needle aspiration biopsies from the investigational INSIGHT study

7. Genetic risk factors for NAFLD and clinically significant fibrosis in persons living with HIV

8. Outcomes of early vs late treatment initiation in solid organ transplantation from HCV NAT+ donors to HCV-uninfected recipients: results from the HCV-TARGET study

9. Hepatitis B e Antigen-Negative Single Hepatocyte Analysis Shows Transcriptional Silencing and Slow Decay of Infected Cells With Treatment

13. Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study

15. Evaluation of a pilot emergency department linkage to care program for patients previously diagnosed with Hepatitis C

16. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

18. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

19. Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B

20. Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017–2019

21. Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus Coinfection

22. Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments

24. Contributors

25. Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs

26. Hepatitis B Virus/Hepatitis D Virus–Coinfected Liver Transplant Candidate Receiving Hepatitis B Virus-Deoxyribonucleic Acid–Positive Allograft and Treated With High-Dose Hepatitis B Immune Globulin

27. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre– or post–liver transplant

29. Single hepatocytes show persistence and transcriptional inactivity of hepatitis B

30. Contributors

33. CONTRIBUTORS

35. Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland

37. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine

38. Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus–HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation

40. Unreported alcohol use was common but did not impact hepatitis C cure in HIV‐infected persons who use drugs

41. 742 ACTIVE HBV TRANSCRIPTION AND TRANSLATION PERSIST DESPITE SUPPRESSION OF VIRAL REPLICATION IN HIV/HBV CO-INFECTED PATIENTS RECEIVING DUALLY ACTIVE ANTIRETROVIRAL THERAPY

42. Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy

45. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy

49. Tu1497 – Efficacy and Safety of Sofosbuvir/Velpatasvir for the Treatment of Patients with Chronic Hepatitis C Genotype 1-6 Infection: Integrated Analysis of Eight Phase 3 Clinical Trials

50. 956 – Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of Hcv Genotype 1-6: Results of the Hcv-Target Study

Catalog

Books, media, physical & digital resources